Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

EP. 1: Advanced RCC: Brief Overview

March 16th 2022

Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).

EP. 2: First-Line Therapy of Advanced RCC With Lenvatinib + Pembrolizumab: CLEAR Study

March 16th 2022

Mehmet A. Bilen, MD, discusses the CLEAR trial that looked at lenvatinib with pembrolizumab as first-line therapy for RCC.

EP. 3: First-Line Therapy of Advanced RCC With Axitinib + Pembrolizumab: KEYNOTE-426 Study

March 23rd 2022

Pedro C. Barata, MD, MSc, reviews the data from the KEYNOTE-426 trial, which focused on axitinib with pembrolizumab.

EP. 4: First-Line Therapy of Advanced RCC With Cabozantinib + Nivolumab: CheckMate 9ER Study

March 23rd 2022

Moshe C. Ornstein, MD, MA, explains the results from the CheckMate 9ER trial that studied cabozantinib with nivolumab.

EP. 5: First-Line Therapy of Advanced RCC With Nivolumab + Ipilimumab: CheckMate 214 Study

March 30th 2022

David Braun, MD, delves into data from the CheckMate 214 trial that focused on ipilimumab with nivolumab.

EP. 6: What Factors Should be Taken Into Consideration When Choosing The Fist-Line Therapy in RCC?

March 30th 2022

Dr Bilen discusses factors to consider when choosing a first-line therapy for advanced clear-cell RCC

EP. 7: Choosing The Appropriate Frontline Therapy in Advanced RCC: IO-TKI vs IO-IO Therapies

April 6th 2022

7.Dr Ornstein explains how he selects between IO-TKI and IO-IO therapy in the first-line setting in advanced RCC.

EP. 8: Treatment Strategies for Patients With RCC and Brain or Bone Metastases

April 6th 2022

Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.

EP. 9: Is There a Role for Biomarkers in Advanced RCC?

April 13th 2022

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with RCC.

EP. 10: Quality of Life Data From Clinical Trials in RCC

April 13th 2022

Dr Ornstein weighs in on interpreting quality of life data from important RCC trials to help with treatment decision-making.

EP. 11: The Evaluation of Novel Agents and Combination Regimens in the First-Line Setting in RCC

April 20th 2022

The panel elaborates on novel agents and combination treatments that are currently being evaluated for the first-line setting in advanced RCC.

EP. 12: Triplet Regimens in Development for Patients With RCC

April 20th 2022

Mehmet A. Bilen, MD, explains how triplet regiments might impact treatment selection for first line and beyond.

EP. 13: Adjuvant Systemic Therapies for Patients With RCC Post-Nephrectomy

April 27th 2022

Dr Zhang discusses recently approved adjuvant systemic therapy for patients with RCC who have a high risk of recurrence after nephrectomy.

EP. 14: Impact of Adjuvant Therapy on Treatment Selection in Advanced RCC

April 27th 2022

David Braun, MD, touches on how the choice of adjuvant therapy can impact subsequent treatment selection in advanced RCC.

EP. 15: Ongoing Clinical Trials in the Adjuvant Setting in RCC

May 4th 2022

Dr Bilen reviews some ongoing trials looking into monotherapy and combination therapies in the adjuvant setting in RCC.

EP. 16: Ongoing Clinical Trials in the Neoadjuvant Setting in RCC

May 4th 2022

Pedro Barata, MD, MSc, provides a brief overview of ongoing trials in the neoadjuvant setting in patients with RCC.

EP. 17: The Impact of Neoadjuvant Therapy on Treatment Selection in Advanced RCC

May 11th 2022

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.

EP. 18: Treatment Options in the Second-Line and Beyond in Advanced RCC

May 11th 2022

Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.

EP. 19: Sequencing Therapies in the Second Line and Beyond in Advanced RCC

May 18th 2022

Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.

EP. 20: Is There a Role for Cabozantinib in the First-Line Setting in Advanced RCC in Certain Populations?

May 18th 2022

Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.